Spring 2024 COVID-19 vaccination campaign: mRNA vaccines for adults and young people: knowledge session
Session information
- Title:
- Spring 2024 COVID-19 vaccination campaign: mRNA vaccines for adults and young people: knowledge session
- Description:
-
This session provides specific information about the mRNA COVID-19 vaccines for administration during the spring 2024 vaccination campaign to those aged 12 years and above. The vaccines are:
• Pfizer-BioNTech mRNA (Comirnaty) Omicron XBB.1.5 vaccine, 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified). This will generally be referred to as Comirnaty XBB.1.5 30 micrograms/dose throughout this session and is suitable for adults and young people (eligible individuals aged 12 years and above)
• Moderna Spikevax XBB.1.5 0.1 milligrams/millilitre dispersion for injection COVID-19 mRNA Vaccine. This will generally be referred to as Spikevax XBB.1.5 50 micrograms/dose throughout this session and is suitable for adults (eligible individuals aged 18 years and above)
Within this session, except where it is necessary to specify the vaccine product, these will be collectively referred to as (the) mRNA vaccines.
This session is designed to provide healthcare workers with the knowledge they need to administer these vaccines safely and effectively to eligible individuals. It will cover key information including how the vaccines work, how they should be stored, prepared and administered and any contraindications, precautions and potential vaccine reactions.
The Core Knowledge session covers key areas including legal aspects of vaccination. The Core Knowledge session must therefore be completed in addition to this vaccine-specific session by any staff member new to COVID-19 vaccination. It may also be freely consulted by experienced COVID-19 vaccinators wishing to revise any aspect of their knowledge.
After completing this session about the 2024 spring vaccination campaign for adults and young people you should complete the accompanying knowledge assessment(s) for the vaccine(s) that you will be administering.
It is important to note that the different types of COVID-19 vaccine have different storage, preparation and administration requirements. Vaccines produced by the same manufacturer, including those with similar brand names, may, too, have different requirements. You must be familiar with the specific recommendations for the COVID-19 vaccine(s) you are delivering. - Hierarchy:
- Coronavirus (COVID-19) > COVID-19 Vaccination > Spring 2024 COVID-19 vaccination campaign: Pfizer BioNTech Comirnaty XBB.1.5 30 micrograms/dose mRNA vaccine: assessment > Spring 2024 COVID-19 vaccination campaign: mRNA vaccines for adults and young people: knowledge session
- Author(s):
-
Lesley McFarlane
Michelle Falconer
Laura Craig
- Created:
- 30 Nov 2020
- Last Major Update:
- 9 Apr 2024
- Keywords:
- 099-0003, COVID, 19, coronavirus, vaccine, vaccination, immuniser, immunisation, Pfizer
- Quicklink:
- 099-0003
Share this item
- Copy URL
Overall rating
4.6/5
4.6/5
Content
4.6/5
4.6/5
Presentation
4.6/5
4.6/5
Interactivity
4.5/5
4.5/5
Self assessments
4.5/5
4.5/5
Overall rating
4.6/5
4.6/5
Content
4.6/5
4.6/5
Presentation
4.6/5
4.6/5
Interactivity
4.5/5
4.5/5
Self assessments
4.5/5
4.5/5
- Title:
- Spring 2024 COVID-19 vaccination campaign: mRNA vaccines for adults and young people: knowledge session
- Description:
-
This session provides specific information about the mRNA COVID-19 vaccines for administration during the spring 2024 vaccination campaign to those aged 12 years and above. The vaccines are:
• Pfizer-BioNTech mRNA (Comirnaty) Omicron XBB.1.5 vaccine, 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified). This will generally be referred to as Comirnaty XBB.1.5 30 micrograms/dose throughout this session and is suitable for adults and young people (eligible individuals aged 12 years and above)
• Moderna Spikevax XBB.1.5 0.1 milligrams/millilitre dispersion for injection COVID-19 mRNA Vaccine. This will generally be referred to as Spikevax XBB.1.5 50 micrograms/dose throughout this session and is suitable for adults (eligible individuals aged 18 years and above)
Within this session, except where it is necessary to specify the vaccine product, these will be collectively referred to as (the) mRNA vaccines.
This session is designed to provide healthcare workers with the knowledge they need to administer these vaccines safely and effectively to eligible individuals. It will cover key information including how the vaccines work, how they should be stored, prepared and administered and any contraindications, precautions and potential vaccine reactions.
The Core Knowledge session covers key areas including legal aspects of vaccination. The Core Knowledge session must therefore be completed in addition to this vaccine-specific session by any staff member new to COVID-19 vaccination. It may also be freely consulted by experienced COVID-19 vaccinators wishing to revise any aspect of their knowledge.
After completing this session about the 2024 spring vaccination campaign for adults and young people you should complete the accompanying knowledge assessment(s) for the vaccine(s) that you will be administering.
It is important to note that the different types of COVID-19 vaccine have different storage, preparation and administration requirements. Vaccines produced by the same manufacturer, including those with similar brand names, may, too, have different requirements. You must be familiar with the specific recommendations for the COVID-19 vaccine(s) you are delivering. - Hierarchy:
- Coronavirus (COVID-19) > COVID-19 Vaccination > Spring 2024 COVID-19 vaccination campaign: Pfizer BioNTech Comirnaty XBB.1.5 30 micrograms/dose mRNA vaccine: assessment > Spring 2024 COVID-19 vaccination campaign: mRNA vaccines for adults and young people: knowledge session
- Author(s):
-
Lesley McFarlane
Michelle Falconer
Laura Craig
- Created:
- 30 Nov 2020
- Last Major Update:
- 9 Apr 2024
- Keywords:
- 099-0003, COVID, 19, coronavirus, vaccine, vaccination, immuniser, immunisation, Pfizer
- Quicklink:
- 099-0003